Genomtec (GMT) Q2 2026 earnings summary

Executive summary

• Group continued R&D activities in biotechnology and medical devices, focusing on the Genomtec ID diagnostic platform, which is in the industrialization phase with an external partner.

• No seasonality or cyclicality in operations; business is funded by equity, grants, and recent share issuance.

• Group structure unchanged; 100% ownership in two subsidiaries focused on scientific research.

Financial highlights

• Consolidated revenue from sales: 27k PLN for H1 2026, unchanged year-over-year.

• Net loss for H1 2026: (4,267)k PLN, improved from (6,555)k PLN in H1 2025.

• Cash and equivalents at period end: 14,244k PLN, up from 4,722k PLN at 2025 year-end.

• Equity increased to 15,671k PLN from 9,214k PLN at 2025 year-end, mainly due to new share issuance.

Outlook and guidance

• Management expects continued negative results and cash outflows until commercialization of developed technologies.

• Additional capital may be raised through further share issues to finance commercialization.

• Group aims to reach break-even after successful commercialization.